Lindahl advises Dicot Pharma AB on rights issue

The rights issue relates to units consisting of shares and warrants. Provided that the issue is fully subscribed for, Dicot Pharma will receive proceeds of approximately SEK 122.6 million. The Company has received subscription commitments and guarantee commitments amounting to approximately SEK 79.8 million, corresponding to approximately 65 percent of the rights issue.

Dicot Pharma is a pharmaceutical company that is developing the candidate LIB-01 into a new modern potency drug. Dicot's main strategy is to develop LIB-01 in-house, up to and including a clinical phase 2a study and thereafter, in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further into a registered drug for the world market. The company's shares are listed on the Spotlight Stock Market.

Lindahl's team consists of Mattias Prage, Michaela Larsson and Olle Swärd Brattström.